Anavex Life Sciences Corp (AVXL)

[OFP]

If you by he mean Dr. Missling, he is not co-opting anything. The PR is quoting an external research paper.

“These new results provide converging evidence on mechanism of action as well as possible disease-modifying properties potentially by restoring homeostasis by means of the sigma-1 receptor agonists in our pipeline. This data also provides a foundation for our ongoing translational research efforts,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.
He is claiming S1R agonism as a MOA...

Those are not results of the study...that is application of the results to implications for 2-73 and it's MOA by Missling. Repeating what I said in regard to this: "That is fine as long as you don't expect 2-73 to outperform other S1R agonists."...he didn't say it's unique, nor could he, nor should anyone assume so until there is actual evidence of it.